Please assess the completion status of the following clinical trial:

Trial Title: A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed cHL, sALCL, or other CD30-expressing PTCL~* Previously treated with brentuximab vedotin containing regimen, with evidence of objective response, and subsequent disease progression or relapse after discontinuing treatment~* Documentation of disease relapse or progression ≥6 months after the last dose of brentuximab vedotin~* Fluorodeoxyglucose positron emission tomography- (FDG-PET) avid and bidimensional measurable disease of at least 1.5 cm in longest axis as documented by radiographic technique~* Eastern Cooperative Oncology Group (ECOG) performance status of less than or equal to 2~* Must not be pregnant and, if of childbearing or fathering potential, must agree to use 2 effective contraception methods during study and for 6 months following last dose of study drug~Exclusion Criteria:~* Previously discontinued brentuximab vedotin due to any Grade 3 or higher toxicity~* Existing Grade 2 or higher peripheral neuropathy~* Previously refractory to treatment with brentuximab vedotin~* History of a cerebral vascular event, unstable angina, or myocardial infarction within 6 months prior to first dose~* History of another malignancy within 3 years before first dose of study drug or any evidence of residual disease from previously diagnosed malignancy~* Acute or chronic graft-versus-host-disease (GvHD) or receiving immunosuppressive therapy as treatment for or prophylaxis agent against GvHD~* Active cerebral/meningeal disease~* History of progressive multifocal leukoencephalopathy (PML)~* Active uncontrolled Grade 3 (per NCI CTCAE v5.0) or higher viral, bacterial, or fungal infection within 2 weeks prior to first dose of study drug~* Chemotherapy, radiotherapy, biologics, and/or other antitumor treatment with immunotherapy that is not completed 4 weeks prior to first dose of study drug, unless underlying disease has progressed on treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Brentuximab vedotin (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).